Genetically engineered t cells having improved persistence in culture
AssigneeCrispr Therapeutics AG
InventorsJonathan Alexander Terrett, Demetrios Kalaitzidis, Hanspeter Waldner
Life of this patent
Estimating the term…
Loading patent…
AssigneeCrispr Therapeutics AG
InventorsJonathan Alexander Terrett, Demetrios Kalaitzidis, Hanspeter Waldner
Estimating the term…
A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).
A population of genetically engineered T cells, comprising:
21-33. (canceled)
35-44. (canceled)
(canceled)
A guide RNA (gRNA) targeting a TET2 gene, comprising a nucleotide sequence specific to exon 3 or exon 5 of the TET2 gene.
49-64. (canceled)
Dependencies are inferred from the claim text.